Melanoma Clinical Trials in Detroit

Showing 141-160 of 297 trials

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

NCT04198818

This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.

Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more

Haihe Biopharma Co., Ltd.37 participantsStarted Jan 2020

Lafayette, Indiana, United States • Detroit, Michigan, United States • Shanghai, China

TERMINATEDPhase 4< 1 mile

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

NCT01856023

Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy. Treatment Arm 1: "HD IL-2 first, then ipilimumab" Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab. Treatment Arm 2: Ipilimumab first then HD IL-2 Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.

Metastatic Melanoma

Clinigen, Inc.29 participantsStarted May 2013

Tucson, Arizona, United States • La Jolla, California, United States • Miami Beach, Florida, United States +9 more locations

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Melanoma Trials in Other Cities

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

Other Conditions in Detroit